Literature DB >> 31148183

A Noncoding Regulatory RNAs Network Driven by Circ-CDYL Acts Specifically in the Early Stages Hepatocellular Carcinoma.

Yanping Wei1,2,3, Xin Chen1,2, Chi Liang1,2, Yan Ling1,2, Xinwei Yang4, Xiaofei Ye5, Hailing Zhang6, Pinghua Yang4, Xiuliang Cui1,2, Yibing Ren1,2, Xianglei Xin4, Hengyu Li6, Ruoyu Wang4, Wenjing Wang7, Feng Jiang8, Suiyi Liu4, Jing Ding1,2, Baohua Zhang4, Liang Li1,2, Hongyang Wang1,2,9.   

Abstract

Hepatocellular carcinoma (HCC) is one of the fastest-rising causes of cancer-related death worldwide, but its deficiency of specific biomarkers and therapeutic targets in the early stages lead to severe inadequacy in the early diagnosis and treatment of HCC. Covalently closed circular RNA (circRNA), which was once considered an aberrant splicing by-product, is now drawing new interest in cancer research because of its remarkable functionality. Beneath the surface of the dominant functional proteins events, a hidden circRNA-centric noncoding regulatory RNAs network active in the very early stage of HCC is here revealed by a genome-wide analysis of mRNA, circRNA, and microRNA (miRNA) expression profiles. Circ-CDYL (chromodomain Y like) is specifically up-regulated in the early stages of HCC and therefore contributes to the properties of epithelial cell adhesion molecule (EPCAM)-positive liver tumor-initiating cells. Circ-CDYL interacts with mRNAs encoding hepatoma-derived growth factor (HDGF) and hypoxia-inducible factor asparagine hydroxylase (HIF1AN) by acting as the sponge of miR-892a and miR-328-3p, respectively. Subsequently, activation of the phosphoinositide 3-kinase (PI3K)-AKT serine/threonine kinase-mechanistic target of rapamycin kinase complex 1/β-catenin and NOTCH2 pathways, which promote the expression of the effect proteins, baculoviral IAP repeat containing 5 (BIRC5 or SURVIVIN) and MYC proto-oncogene, is influenced by circ-CDYL. A treatment incorporating circ-CDYL interference and traditional enzyme inhibitors targeting PI3K and HIF1AN demonstrated highly effective inhibition of stem-like characteristics and tumor growth in HCC. Finally, we demonstrated that circ-CDYL expression or which combined with HDGF and HIF1AN are both independent markers for discrimination of early stages of HCC with the odds ratios of 1.09 (95% confidence interval [CI], 1.02-1.17) and 124.58 (95% CI, 13.26-1170.56), respectively.
Conclusion: These findings uncover a circRNA-centric noncoding regulatory RNAs network in the early stages of HCC and thus provide a possibility for surveillance and early treatment of HCC.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31148183     DOI: 10.1002/hep.30795

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  64 in total

1.  pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma.

Authors:  Mingfang Wu; Chen Zhong; Qian Zhang; Lu Wang; Lingling Wang; Yanjie Liu; Xiaoxue Zhang; Xiuhua Zhao
Journal:  J Nanobiotechnology       Date:  2021-02-06       Impact factor: 10.435

2.  Circular RNA circ-CDYL sponges miR-1180 to elevate yes-associated protein in multiple myeloma.

Authors:  Fang Chen; Xiaohui Wang; Shuang Fu; Shaokun Wang; Yu Fu; Jihong Zhang; Zhuogang Liu
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-22

3.  Competing Endogenous RNA (ceRNA) Network Analysis of Autophagy-Related Genes in Hepatocellular Carcinoma.

Authors:  Chenyu Yang; Qian Dong; Chengzhan Zhu; Yixiu Wang; Weijie Xue; Yuwei Xie
Journal:  Pharmgenomics Pers Med       Date:  2020-10-13

Review 4.  Circular RNAs and their participation in stemness of cancer.

Authors:  Francisco Alejandro Lagunas-Rangel
Journal:  Med Oncol       Date:  2020-04-07       Impact factor: 3.064

5.  Hepatocellular Carcinoma-associated microRNAs Induced by Hepatoma-derived Growth Factor Stimulation.

Authors:  Hirayuki Enomoto; Hideji Nakamura; Hiroki Nishikawa; Takashi Nishimura; Yoshinori Iwata; Shuhei Nishiguchi; Hiroko Iijima
Journal:  In Vivo       Date:  2020 Sep-Oct       Impact factor: 2.155

6.  A novel HDGF-ALCAM axis promotes the metastasis of Ewing sarcoma via regulating the GTPases signaling pathway.

Authors:  Yang Yang; Yuedong Ma; Huabin Gao; Tingsheng Peng; Huijuan Shi; Yunxiang Tang; Hui Li; Lin Chen; Kaishun Hu; Anjia Han
Journal:  Oncogene       Date:  2020-11-25       Impact factor: 9.867

7.  Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis.

Authors:  Ning Lyu; Yan Zeng; Yanan Kong; Qifeng Chen; Haijing Deng; Shunling Ou; Yanfang Bai; Hailin Tang; Xiaolan Wang; Ming Zhao
Journal:  Ann Transl Med       Date:  2021-04

8.  CircMEMO1 modulates the promoter methylation and expression of TCF21 to regulate hepatocellular carcinoma progression and sorafenib treatment sensitivity.

Authors:  Zhao-Ru Dong; Ai-Wu Ke; Tao Li; Jia-Bing Cai; Ya-Fei Yang; Wei Zhou; Guo-Ming Shi; Jia Fan
Journal:  Mol Cancer       Date:  2021-05-13       Impact factor: 27.401

Review 9.  Circular RNAs in Hepatocellular Carcinoma: Emerging Functions to Clinical Significances.

Authors:  Yucheng Zhang; Yali Wang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

10.  Circular noncoding RNA hsa_circ_0005986 as a prognostic biomarker for hepatocellular carcinoma.

Authors:  Gyeonghwa Kim; Ja Ryung Han; Soo Young Park; Won Young Tak; Young-Oh Kweon; Yu Rim Lee; Young Seok Han; Jung Gil Park; Min Kyu Kang; Hye Won Lee; Won Kee Lee; Deokhoon Kim; Se Young Jang; Keun Hur
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.